Barclays Downgrades Dexcom (DXCM) to Underweight Citing Intensifying Competition in Core Segments

DexCom Inc. (NASDAQ:DXCM) is one of the best US stocks to buy and hold in 2026. On January 12, Barclays downgraded DexCom to Underweight from Equal Weight with a price target of $71, which was brought down from $80. The firm anticipated that intensifying competition within Dexcom’s primary insulin-intensive segments throughout 2026 and 2027 would limit the stock’s valuation multiple and hinder its performance in the near-to-medium term.

On January 9, Bernstein adjusted its outlook for DexCom, increasing the price target to $86 from $84 while maintaining an Outperform rating. This update came as US healthcare stocks showed signs of recovery following a significant low point in September 2025. The firm noted that as the macroeconomic and policy uncertainties that hampered the sector throughout 2025 begin to clear, healthcare equities are well-positioned for a stronger performance in 2026.

Barclays Downgrades Dexcom (DXCM) to Underweight Citing Intensifying Competition in Core Segments

jason-briscoe-Gw_sFen8VhU-unsplash

Furthermore, on January 7, RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on DexCom Inc. (NASDAQ:DXCM) while setting a price target of $85.

DexCom Inc. (NASDAQ:DXCM) is a medical device company that focuses on the design, development, and commercialization of CGM (continuous glucose monitoring) systems in the US and internationally.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.